Celldex Therapeutics, Inc (CLDX)
Celldex Therapeutics, Inc. is a biotechnology company focused on developing targeted immunotherapies for cancer and other diseases. The company specializes in monoclonal antibodies, recombinant proteins, and vaccine technologies to stimulate the immune system's ability to fight tumors. Founded in 2004 and based in Hampton, New Jersey, Celldex aims to advance innovative treatments through a pipeline of clinical and preclinical candidates.
Company News
The global CIndU market is experiencing significant growth driven by advancements in diagnostic tools, biologic therapies, and increasing awareness of immune mechanisms, with emerging personalized medicine approaches promising improved patient outcomes.
Analysts have released a range of ratings for Celldex Therapeutics, with an average 12-month price target of $77.4. The company's financial performance shows challenges, with a decline in revenue and below-industry net margin, but strong return on equity and assets.
The mean of analysts' price targets for Celldex (CLDX) points to an 87.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The biotech's CSU treatment advanced in the laboratory.